Table 1.

Demographics of 48 Adults Receiving Veliparib/Temozolomide

Age (median, range)	69 (20–88)
Male/Female	23/25
Disease Category
AML de novo	17 (35%; 1 T-ALL/AML)
Secondary AML	31 (65%)
MDS	13 (27%)
t-MDS/AML	9 (19%)
MPN	3 (6%)
CMML	6 (13%)
Prior Anti-Leukemia (MDS) Therapy*
None	2 (4%)
Cytotoxic Chemotherapy	33 (69%; 3*)
Demethylating Agents	30 (63%; 4*)
Allogeneic SCT	9 (19%)
Disease Status (n=39; previously treated for AML)
1st Relapse	12 (31%; 10#)
≥ 2 Relapse	5 (13%; 4#)
1° Refractory	12 (31%; 7&)
Multiply Refractory	10 (25%)
Median duration CR1	10 (1.5–41) months
Genetics
Favorable	1 (2%; inv16, c-KIT+)
Intermediate	20 (42%; 13 normal karyotype)
FLT3-ITD	4** (10%; 40 tested)
NPM1	2** (7%; 29 tested)
Adverse	27 (56%)
Single	6
Complex (≥ 3)	9
Monosomal karyotype	2

^*7 patients received only therapy for MDS or MPN;

^#refractory relapse;

^&received only demethylating agents;

^**1 both FLT-3 and NPM1 mutation